Previous 10 | Next 10 |
Calliditas announces termination of the proposed global offering PR Newswire STOCKHOLM , Jan. 28, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX - CALTX; Nasdaq - CALT) today announced that despite significant interest, it wil...
Calliditas Therapeutics ([[CALT]] -10.3%) launched a proposed public offering of American Depositary Shares (representing two common shares), in the U.S. for trading on Nasdaq Global Select Market and a concurrent private placement of common shares (global offering).Size of the glob...
Calliditas Therapeutics launches proposed global offering PR Newswire STOCKHOLM , Jan. 26, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX: CALTX) (Nasdaq: CALT) will today launch a proposed public offering of American Depo...
Calliditas Therapeutics ([[CALT]]) has announced that all 360 patients have been enrolled for the global Phase 3 trial NefIgArd comprising Part A and Part B, evaluating the effect of Nefecon versus placebo in patients with primary IgA nephropathy (IgAN).Calliditas read out topline data from P...
Calliditas Announces Full Enrollment of the Phase 3 NefIgArd Trial PR Newswire STOCKHOLM , Jan. 21, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX: CALTX) (NASDAQ: CALT) today announced that all 360 patients have been enro...
Calliditas announces clinical development plan for setanaxib and comments on data from Part A of NefIgArd study at today´s R&D Day Calliditas announces clinical development plan for setanaxib and comments on data from Part A of NefIgArd study at today´s R&D Day...
Calliditas Therapeutics' ([[CALT]] +6.4%) subsidiary Genkyotex has announced positive Phase 1 data demonstrating a favorable safety and pharmacokinetic profile of high-dose setanaxib, Genkyotex's lead asset.The study in 46 healthy volunteers demonstrated that setanaxib is well tolerated ...
Positive Phase 1 results in high-dose setanaxib trial PR Newswire STOCKHOLM , Jan. 18, 2021 /PRNewswire/ -- Genkyotex SA, a subsidiary of Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX - CALTX; NASDAQ - CALT), today announced positive Phase 1 data...
Agenda for Calliditas virtual R&D Day on January 20, 2021 Agenda for Calliditas virtual R&D Day on January 20, 2021 PR Newswire STOCKHOLM , Jan. 15, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX - CALTX) (NASDAQ...
Calliditas announces final outcome of simplified mandatory offer to the shareholders of Genkyotex STOCKHOLM , Dec. 16, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX - CALTX; NASDAQ - CALT) submitted a simplified public mandatory offe...
News, Short Squeeze, Breakout and More Instantly...
Calliditas Therapeutics AB Company Name:
CALT Stock Symbol:
NASDAQ Market:
Launch of Phase 3 clinical trial with Nefecon in Japan PR Newswire STOCKHOLM , July 4, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatri...
2024-06-30 09:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Calliditas provides setanaxib patent update PR Newswire STOCKHOLM , June 18, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the United States Patent and Trademark Office (USPTO) h...